Krystal Biotech, Inc. KRYS Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s accounts receivable?
- Krystal Biotech, Inc. (KRYS) reported accounts receivable of $127.02M in Q1 2026.
- How has Krystal Biotech, Inc.'s accounts receivable changed year-over-year?
- Krystal Biotech, Inc.'s accounts receivable increased by 23.0% year-over-year, from $103.26M to $127.02M.
- What does accounts receivable mean?
- The amount of money customers owe the company for products or services already provided.
- How do you interpret accounts receivable?
- An increase relative to sales may indicate collection issues, while a decrease suggests efficient cash collection processes.
- How does accounts receivable compare across companies?
- Varies by industry; biotech companies with commercial products monitor this closely to manage working capital.